TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013
TCL Archive Phase III Study: Rituxan Improved PFS By 79% In Advanced Follicular Lymphoma December 31, 2010
TCL Archive Bush Nominates von Eschenbach For FDA; Democrats Put Hold On Confirmation. von Eschenbach To Step Down As NCI Director, But Details Unavailable; No Acting Director Named. Applause, Outrage, Over Nomination. Now, von Eschenbach Leads A Retreat From 2015 Target Date For His Challenge Goal. March 17, 2006
TCL Archive In Brief: Panel to Meet Jan. 30 In Los Angeles; Fate Of Proposed Urologic Group Depends On Budget January 10, 1986
